NFKB2 (Q00653) variants and mutations
NFKB2 (also known as Q00653) is a human protein-coding gene encoding a nuclear factor NF-kappa-B p100 subunit protein. Processing of its p100 precursor generates p52 for the noncanonical NF-kappaB pathway, which is important for lymphoid-organ development and B-cell biology. Pathogenic variants can cause common variable immunodeficiency with endocrine and autoimmune abnormalities. This analysis covers 1,020 NFKB2 variants and mutations. Of these, 78% have computational variant effect predictions. Disease context includes immunodeficiency, common variable, 10, common variable immunodeficiency, and immunodeficiency disease. Example NFKB2 variants include M1N, E2K, and E2E.
Variant analysis overview
- Gene: NFKB2
- Protein: Q00653
- UniProt accession: Q00653
- Organism: Homo sapiens
- Variants analyzed: 1020
- Variant scope: all variants
- Completed: 2026-08-20
Variant and mutation evidence
- Variant composition: 876 unspecified-consequence records; 1 5 prime utr variant; 74 synonymous variants; 3 splice-region variants; 52 missense variants; 4 in-frame deletions; 4 frameshift variants; 6 substitution
- Prediction scores: 793 variants have prediction scores (78% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: immunodeficiency, common variable, 10, common variable immunodeficiency, immunodeficiency disease, Hodgkins lymphoma, deficiency in anterior pituitary function - variable immunodeficiency syndrome, Deficiency in anterior pituitary function-variable immunodeficiency syndrome, Alzheimer disease, Parkinson disease, inborn error of immunity, colon adenocarcinoma, neurodegenerative disease, bronchiectasis.
Protein structure and variant hotspots
- Protein features: 2 domains; 9 post-translational modification sites.
- Structural context: 362 variants have structural context.
- PTM context: 19 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable NFKB2 variants
Examples include M1N, E2K, E2E, S3I, S3N, S3S, C4R, C4C. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1N (p.Met1Asn), rs1397509779, gnomAD 10-102395959-C-CA, CADD 20.30
- E2K (p.Glu2Lys), rs2061101667, ClinGen CA377895674, ClinVar RCV001240322, Ensembl rs2061101667, AlphaMissense 0.19, MetaLR 0.06, Uncertain significance, Immunodeficiency, common variable, 10
- E2E (p.Glu2Glu), rs1272894735, gnomAD 10-102395965-G-A, CADD 11.50
- S3I (p.Ser3Ile), ExAC rs778625681, TOPMed rs778625681, gnomAD rs778625681, CADD 18.60, PolyPhen-2 0.01
- S3N (p.Ser3Asn), ExAC rs778625681, TOPMed rs778625681, gnomAD rs778625681, CADD 16.20, PolyPhen-2 0.00
- S3S (p.Ser3Ser), rs748114844, gnomAD 10-102395968-T-C, CADD 13.10
- C4R (p.Cys4Arg), Ensembl rs2061101900, CADD 23.40, PolyPhen-2 0.35
- C4C (p.Cys4Cys), gnomAD 10-102395971-C-T, CADD 14.80
- Y5C (p.Tyr5Cys), rs200361192, ClinGen CA5664401, ClinVar RCV000817242, ClinVar RCV003392621, CADD 27.90, PolyPhen-2 0.89, Uncertain significance, Immunodeficiency, common variable, 10
- Y5D (p.Tyr5Asp), rs1455622222, ClinGen CA377895696, ClinVar RCV003845213, AlphaMissense 0.12, MetaLR 0.15, Uncertain significance, Immunodeficiency, common variable, 10
- Y5H (p.Tyr5His), TOPMed rs1455622222, gnomAD rs1455622222, AlphaMissense 0.12, MetaLR 0.15
- Y5N (p.Tyr5Asn), TOPMed rs1455622222, gnomAD rs1455622222, AlphaMissense 0.12, MetaLR 0.15
- N6N (p.Asn6Asn), rs773041008, gnomAD 10-102395977-C-T, CADD 13.00
- P7L (p.Pro7Leu), ExAC rs760413992, gnomAD rs760413992, CADD 23.30, PolyPhen-2 0.12
- G8A (p.Gly8Ala), gnomAD rs2061110103, CADD 15.80, PolyPhen-2 0.00
- G8C (p.Gly8Cys), TOPMed rs922475027, gnomAD rs922475027, CADD 23.60, PolyPhen-2 0.00, Uncertain significance
- G8R (p.Gly8Arg), rs922475027, ClinGen CA377895726, ClinVar RCV002027539, ClinVar RCV005445573, CADD 23.40, PolyPhen-2 0.00, Uncertain significance, Inborn genetic diseases; Immunodeficiency, common variable, 10
- G8S (p.Gly8Ser), TOPMed rs922475027, gnomAD rs922475027, CADD 22.30, PolyPhen-2 0.00, Uncertain significance
- G8G (p.Gly8Gly), rs1315504895, gnomAD 10-102396255-T-G, CADD 15.30
- L9P (p.Leu9Pro), Ensembl rs1565204154
- L9V (p.Leu9Val), gnomAD 10-102396256-C-G, MetaLR 0.14, MetaSVM -1.01
- L9R (p.Leu9Arg), gnomAD 10-102396257-T-G, MetaLR 0.16, MetaSVM -0.79
- L9L (p.Leu9Leu), gnomAD 10-102396258-G-C, CADD 10.50
- D10G (p.Asp10Gly), rs1167402841, ClinGen CA377895740, ClinVar RCV003745752, TOPMed rs1167402841, CADD 33.00, PolyPhen-2 0.70, Uncertain significance, Immunodeficiency, common variable, 10
- D10N (p.Asp10Asn), rs2061110285, ClinGen CA377895736, ClinVar RCV003583849, TOPMed rs2061110285, AlphaMissense 0.11, MetaLR 0.07, Uncertain significance, Immunodeficiency, common variable, 10
- G11S (p.Gly11Ser), gnomAD 10-102396262-G-A, MetaLR 0.20, MetaSVM -0.70
- G11V (p.Gly11Val), gnomAD 10-102396263-G-T, MetaLR 0.20, MetaSVM -0.70
- G11G (p.Gly11Gly), rs2061110399, gnomAD 10-102396264-T-C, CADD 9.77
- I12T (p.Ile12Thr), TOPMed rs2061110488, CADD 21.90, PolyPhen-2 0.06
- I12V (p.Ile12Val), rs2544575068, ClinGen CA377895751, ClinVar RCV003400364, Uncertain significance, NFKB2-related disorder
- I13del (p.Ile13del), rs1415928008, gnomAD 10-102396263-GTAT, CADD 18.20
- I13T (p.Ile13Thr), gnomAD 10-102396269-T-C, MetaLR 0.05, MetaSVM -1.02
- E14K (p.Glu14Lys), rs45581936, ClinGen CA5664426, ClinVar RCV000525183, UniProt VAR 022223, CADD 24.90, PolyPhen-2 0.03, Benign, Immunodeficiency, common variable, 10
- E14Q (p.Glu14Gln), 1000Genomes rs45581936, ESP rs45581936, ExAC rs45581936, TOPMed rs45581936, CADD 22.90, PolyPhen-2 0.08, Benign
- Y15N (p.Tyr15Asn), ExAC rs762964415, TOPMed rs762964415, gnomAD rs762964415, CADD 26.10, PolyPhen-2 0.45
- Y15H (p.Tyr15His), gnomAD 10-102396274-T-C, MetaLR 0.14, MetaSVM -0.87
- Y15Y (p.Tyr15Tyr), rs764595866, gnomAD 10-102396276-T-C, CADD 9.07
- D16E (p.Asp16Glu), rs774734354, ClinGen CA377895785, ClinVar RCV003090376, ExAC rs774734354, CADD 19.40, Uncertain significance, Immunodeficiency, common variable, 10
- D17del (p.Asp17del), rs1565204193, gnomAD 10-102396274-TATG, CADD 22.10
- D17Y (p.Asp17Tyr), gnomAD 10-102396280-G-T, MetaLR 0.19, MetaSVM -0.75
- D17D (p.Asp17Asp), rs762442104, gnomAD 10-102396282-T-C, CADD 11.20
- F18V (p.Phe18Val), gnomAD 10-102396283-T-G, MetaLR 0.06, MetaSVM -0.99
- F18Y (p.Phe18Tyr), gnomAD 10-102396284-T-A, MetaLR 0.07, MetaSVM -1.04
- F18F (p.Phe18Phe), gnomAD 10-102396285-C-T, CADD 15.00
- K19R (p.Lys19Arg), gnomAD 10-102396287-A-G, MetaLR 0.06, MetaSVM -1.04
- K19K (p.Lys19Lys), rs1330590924, gnomAD 10-102396288-A-G, CADD 12.20
- L20F (p.Leu20Phe), gnomAD rs1297472674, CADD 7.25, PolyPhen-2 0.00
- L20W (p.Leu20Trp), TOPMed rs1424290307, gnomAD rs1424290307, CADD 23.70
- L20L (p.Leu20Leu), rs2061110972, gnomAD 10-102396289-T-C, CADD 13.00
- L20S (p.Leu20Ser), gnomAD 10-102396290-T-C, MetaLR 0.05, MetaSVM -1.02
- N21D (p.Asn21Asp), gnomAD rs1355876416, CADD 15.50, PolyPhen-2 0.00
- N21S (p.Asn21Ser), rs577190240, ClinGen CA5664431, ClinVar RCV001996158, ClinVar RCV005242148, CADD 14.20, PolyPhen-2 0.00, Uncertain significance, Immunodeficiency, common variable, 10; not provided
- S22Y (p.Ser22Tyr), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- S22F (p.Ser22Phe), gnomAD 10-102396296-C-T, MetaLR 0.07, MetaSVM -1.00
- S22S (p.Ser22Ser), rs750859613, gnomAD 10-102396297-C-T, CADD 8.75
- S23Y (p.Ser23Tyr), NCI-TCGA Cosmic COSV5187, cosmic curated COSV51870, Variant assessed as somatic; moderate impact.
- S23del (p.Ser23del), gnomAD 10-102396293-ACTC, CADD 16.60
- S23C (p.Ser23Cys), gnomAD 10-102396299-C-G, MetaLR 0.07, MetaSVM -1.09
- I24V (p.Ile24Val), gnomAD rs867399655, CADD 16.00, PolyPhen-2 0.00
- I24F (p.Ile24Phe), gnomAD 10-102396301-A-T, MetaLR 0.05, MetaSVM -1.07
- I24T (p.Ile24Thr), gnomAD 10-102396302-T-C, MetaLR 0.07, MetaSVM -1.04
- I24I (p.Ile24Ile), rs2061111685, gnomAD 10-102396303-T-C, CADD 10.70
- V25A (p.Val25Ala), rs1379133748, ClinGen CA377895846, ClinVar RCV000814454, ClinVar RCV003258988, CADD 18.20, PolyPhen-2 0.00, Uncertain significance, Inborn genetic diseases; Immunodeficiency, common variable, 10
- E26Q (p.Glu26Gln), TOPMed rs1043473460
- P27S (p.Pro27Ser), TOPMed rs902187555, gnomAD rs902187555, CADD 22.40, PolyPhen-2 0.04
- P27P (p.Pro27Pro), rs1010867503, gnomAD 10-102396312-C-G, CADD 11.90
- K28Q (p.Lys28Gln), gnomAD 10-102396313-A-C, MetaLR 0.05, MetaSVM -1.07
- K28R (p.Lys28Arg), gnomAD 10-102396314-A-G, MetaLR 0.07, MetaSVM -1.06
- K28K (p.Lys28Lys), rs2061112217, gnomAD 10-102396315-G-A, CADD 12.10
- E29Q (p.Glu29Gln), rs2061112300, ClinGen CA377895869, ClinVar RCV001052335, TOPMed rs2061112300, AlphaMissense 0.11, MetaLR 0.08, Uncertain significance, Immunodeficiency, common variable, 10
- E29E (p.Glu29Glu), gnomAD 10-102396318-G-A, CADD 8.45
- P30A (p.Pro30Ala), ExAC rs754657770, gnomAD rs754657770, Uncertain significance, Immunodeficiency, common variable, 10
- P30S (p.Pro30Ser), ExAC rs754657770, gnomAD rs754657770, CADD 22.70, PolyPhen-2 0.78
- A31G (p.Ala31Gly), rs1485873314, TOPMed rs1485873314, gnomAD rs1485873314, CADD 15.90, PolyPhen-2 0.01, Uncertain significance, Immunodeficiency, common variable, 10
- A31S (p.Ala31Ser), gnomAD 10-102396322-G-T, MetaLR 0.05, MetaSVM -1.07
- A31T (p.Ala31Thr), gnomAD 10-102396322-G-A, MetaLR 0.06, MetaSVM -1.07
- A31A (p.Ala31Ala), gnomAD 10-102396324-C-G, CADD 8.51
- P32S (p.Pro32Ser), gnomAD rs2061112538, CADD 14.10
- E33K (p.Glu33Lys), Ensembl rs55877362
- E33Q (p.Glu33Gln), gnomAD 10-102396328-G-C, MetaLR 0.13, MetaSVM -1.03
- T34N (p.Thr34Asn), gnomAD 10-102396328-G-GA, CADD 26.20
- A35T (p.Ala35Thr), TOPMed rs1243363991, gnomAD rs1243363991, CADD 31.00, PolyPhen-2 0.02
- D36N (p.Asp36Asn), rs2135428891, ClinGen CA377895924, ClinVar RCV001760808, Ensembl rs2135428891, AlphaMissense 0.09, MetaLR 0.09, Uncertain significance, not provided
- G37G (p.Gly37Gly), rs1453209890, gnomAD 10-102396456-C-T, CADD 9.73
- Y39H (p.Tyr39His), gnomAD 10-102396460-T-C, MetaLR 0.18, MetaSVM -0.85
- Y39Y (p.Tyr39Tyr), rs751118528, gnomAD 10-102396462-C-T, CADD 12.00
- L40L (p.Leu40Leu), rs368708648, gnomAD 10-102396463-C-T, CADD 13.60
- V41M (p.Val41Met), ExAC rs745622070, TOPMed rs745622070, gnomAD rs745622070, CADD 24.60, PolyPhen-2 0.93
- V41V (p.Val41Val), gnomAD 10-102396468-G-A, CADD 14.10
- I42F (p.Ile42Phe), gnomAD rs1396772862, CADD 28.90
- I42L (p.Ile42Leu), gnomAD 10-102396469-A-C, MetaLR 0.39, MetaSVM -0.23
- I42T (p.Ile42Thr), gnomAD 10-102396470-T-C, MetaLR 0.46, MetaSVM 0.01
- I42I (p.Ile42Ile), rs976488499, gnomAD 10-102396471-C-T, CADD 4.26
- V43M (p.Val43Met), gnomAD 10-102396472-G-A, MetaLR 0.20, MetaSVM -0.70
- Q48* (p.Gln48Ter), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- Q48P (p.Gln48Pro), rs755916743, ClinGen CA5664462, ClinVar RCV002000659, ClinVar RCV004641852, CADD 32.00, PolyPhen-2 1.00, Uncertain significance, Inborn genetic diseases; Immunodeficiency, common variable, 10
- R49K (p.Arg49Lys), NCI-TCGA Cosmic COSV9950, cosmic curated COSV99503, Variant assessed as somatic; moderate impact.
- R49T (p.Arg49Thr), rs2544577178, ClinGen CA377896026, ClinVar RCV002284795, ClinVar RCV003101637, CADD 34.00, PolyPhen-2 0.99, Uncertain significance, not provided; Immunodeficiency, common variable, 10
- R52* (p.Arg52Ter), cosmic curated COSV51873, ExAC rs779680880, gnomAD rs779680880
- R52Q (p.Arg52Gln), rs2135429414, ClinGen CA377896045, NCI-TCGA Cosmic COSV5187, cosmic curated COSV51871, CADD 33.00, PolyPhen-2 0.96, Uncertain significance, Immunodeficiency, common variable, 10
- F53F (p.Phe53Phe), rs753714205, gnomAD 10-102396739-T-C, CADD 14.30, SIFT 0.00
- R54* (p.Arg54Ter), rs1337105771, cosmic curated COSV10720, gnomAD rs1337105771, CADD 38.00, Variant assessed as somatic; high impact.
- R54Q (p.Arg54Gln), NCI-TCGA Cosmic COSV5187, cosmic curated COSV51870, Variant assessed as somatic; moderate impact.
- R54R (p.Arg54Arg), gnomAD 10-102396742-A-G, CADD 13.30, SIFT 1.00
- Y55Y (p.Tyr55Tyr), rs755103820, gnomAD 10-102396745-T-C, CADD 12.60, SIFT 0.00
- C57W (p.Cys57Trp), cosmic curated COSV51874, ExAC rs779223172, gnomAD rs779223172, CADD 24.70, PolyPhen-2 1.00
- E58G (p.Glu58Gly), gnomAD rs1438313272
- G59G (p.Gly59Gly), rs1045259718, gnomAD 10-102396757-C-T, CADD 12.30
- S61S (p.Ser61Ser), rs748167631, gnomAD 10-102396763-C-A, CADD 13.40
- H62P (p.His62Pro), Ensembl rs1589859255, CADD 28.70, PolyPhen-2 0.98
- H62R (p.His62Arg), gnomAD 10-102396765-A-G, MetaLR 0.26, MetaSVM -0.50
- H62H (p.His62His), rs772286786, gnomAD 10-102396766-T-C, CADD 2.72
- G63E (p.Gly63Glu), rs1305758604, gnomAD 10-102396766-TG-T, CADD 33.00
- G64R (p.Gly64Arg), NCI-TCGA Cosmic COSV5187, cosmic curated COSV51872, Variant assessed as somatic; moderate impact.
- G64G (p.Gly64Gly), gnomAD 10-102396772-A-G, CADD 13.20
- L65L (p.Leu65Leu), gnomAD 10-102396775-G-A, CADD 10.40
- P66S (p.Pro66Ser), NCI-TCGA Cosmic COSV5187, cosmic curated COSV51873, Variant assessed as somatic; moderate impact.
- P66A (p.Pro66Ala), gnomAD 10-102396776-C-G, MetaLR 0.27, MetaSVM -0.53
- P66P (p.Pro66Pro), gnomAD 10-102396778-C-A, CADD 8.49
- G67R (p.Gly67Arg), gnomAD rs1165226340
- G67S (p.Gly67Ser), gnomAD rs1165226340, CADD 29.90, PolyPhen-2 0.92
- G67K (p.Gly67Lys), gnomAD 10-102396774-TGCC, CADD 32.00
- A68V (p.Ala68Val), cosmic curated COSV51873, gnomAD rs1419527441
- S70C (p.Ser70Cys), rs2135429484, ClinGen CA377896159, ClinVar RCV001356252, Ensembl rs2135429484, CADD 29.30, PolyPhen-2 0.98, Uncertain significance, not provided
- E71D (p.Glu71Asp), gnomAD rs2061123181, CADD 24.40
- K72K (p.Lys72Lys), rs369551276, gnomAD 10-102396796-G-A, CADD 11.20
- G73G (p.Gly73Gly), rs1468635663, gnomAD 10-102396799-C-T, CADD 13.20
- R74G (p.Arg74Gly), NCI-TCGA Cosmic COSV9950, cosmic curated COSV99502, CADD 25.40, PolyPhen-2 0.52, Variant assessed as somatic; moderate impact.
- R74Q (p.Arg74Gln), rs774802098, ClinGen CA212213837, NCI-TCGA Cosmic COSV5187, cosmic curated COSV51871, CADD 23.50, PolyPhen-2 0.01, Uncertain significance, Immunodeficiency, common variable, 10
- R74R (p.Arg74Arg), rs2135429515, gnomAD 10-102396802-A-T, CADD 12.70
- K75R (p.Lys75Arg), gnomAD 10-102396804-A-G, MetaLR 0.13, MetaSVM -0.78
- Y77F (p.Tyr77Phe), 1000Genomes rs202041815
- T79T (p.Thr79Thr), gnomAD 10-102396817-T-C, CADD 9.93
- V80I (p.Val80Ile), TOPMed rs1451149894, gnomAD rs1451149894, CADD 24.70
- I82=, NCI-TCGA TCGA novel, Variant assessed as somatic; low impact.
- I82I (p.Ile82Ile), gnomAD 10-102396906-C-T, CADD 16.40
- C83R (p.Cys83Arg), TOPMed rs2061125193
- N84N (p.Asn84Asn), gnomAD 10-102396912-C-T, CADD 13.10
- Y85Y (p.Tyr85Tyr), rs766359206, gnomAD 10-102396915-C-T, CADD 8.44
- E86* (p.Glu86Ter), 1000Genomes rs200369413, ExAC rs200369413, gnomAD rs200369413, Uncertain significance
- E86K (p.Glu86Lys), rs200369413, ClinGen CA5664503, ClinVar RCV003743425, 1000Genomes rs200369413, CADD 24.40, PolyPhen-2 0.48, Uncertain significance, Immunodeficiency, common variable, 10
- E86V (p.Glu86Val), gnomAD 10-102396917-A-T, MetaLR 0.04, MetaSVM -1.06
- E86E (p.Glu86Glu), gnomAD 10-102396918-G-A, CADD 11.90
- E86D (p.Glu86Asp), gnomAD 10-102396918-G-C, MetaLR 0.05, MetaSVM -1.00
- P88A (p.Pro88Ala), gnomAD rs1369213686, CADD 16.50, PolyPhen-2 0.24
- A89V (p.Ala89Val), TOPMed rs1242603464
- K90K (p.Lys90Lys), rs1565205073, gnomAD 10-102396930-G-A, CADD 12.40
- I91L (p.Ile91Leu), gnomAD 10-102396931-A-C, MetaLR 0.33, MetaSVM -0.39
- I91I (p.Ile91Ile), rs762145275, gnomAD 10-102396933-C-T, CADD 2.15
- V93V (p.Val93Val), rs1313856840, gnomAD 10-102396939-G-A, CADD 11.80
- D94G (p.Asp94Gly), TOPMed rs2061126023
- L95P (p.Leu95Pro), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- L95V (p.Leu95Val), Ensembl rs2061126106
- L95L (p.Leu95Leu), rs2061126216, gnomAD 10-102396945-G-C, CADD 12.60
- T97T (p.Thr97Thr), gnomAD 10-102396951-A-G, CADD 8.32
- H98N (p.His98Asn), rs1589859604, ClinGen CA377896360, ClinVar RCV000816983, Ensembl rs1589859604, AlphaMissense 0.23, MetaLR 0.11, Uncertain significance, Immunodeficiency, common variable, 10
- S99C (p.Ser99Cys), rs2135429749, ClinGen CA377896368, ClinVar RCV001891184, Ensembl rs2135429749, CADD 29.10, PolyPhen-2 0.98, Uncertain significance, Immunodeficiency, common variable, 10
- S99G (p.Ser99Gly), gnomAD 10-102396955-A-G, MetaLR 0.13, MetaSVM -1.01
- D100E (p.Asp100Glu), TOPMed rs1589859611
- P102T (p.Pro102Thr), gnomAD rs1357695101, CADD 23.20, PolyPhen-2 0.90
- R103C (p.Arg103Cys), rs1413174692, ClinGen CA377896398, NCI-TCGA Cosmic COSV5187, cosmic curated COSV51872, CADD 32.00, PolyPhen-2 0.94, Uncertain significance, Immunodeficiency, common variable, 10
- R103G (p.Arg103Gly), TOPMed rs1413174692, gnomAD rs1413174692, Uncertain significance
- R103H (p.Arg103His), ExAC rs779214476, gnomAD rs779214476, CADD 23.00, PolyPhen-2 0.03
- A104S (p.Ala104Ser), gnomAD 10-102396970-G-T, MetaLR 0.18, MetaSVM -0.79
- A104A (p.Ala104Ala), gnomAD 10-102396972-T-C, CADD 13.30
- A106A (p.Ala106Ala), rs1357679057, gnomAD 10-102396978-C-G, CADD 12.40
- H107H (p.His107His), rs1327128300, gnomAD 10-102396981-C-T, CADD 13.50
- L109L (p.Leu109Leu), rs118178925, gnomAD 10-102396985-C-T, CADD 13.70
- Q113P (p.Gln113Pro), gnomAD 10-102396998-A-C, MetaLR 0.18, MetaSVM -0.83
- Q113Q (p.Gln113Gln), gnomAD 10-102396999-A-G, CADD 6.69
- C114C (p.Cys114Cys), gnomAD 10-102397002-C-T, CADD 12.70
- S115L (p.Ser115Leu), rs758763622, ClinGen CA5664507, NCI-TCGA Cosmic COSV5187, cosmic curated COSV51870, CADD 22.90, PolyPhen-2 0.27, Uncertain significance, Immunodeficiency, common variable, 10
- S115W (p.Ser115Trp), gnomAD 10-102397004-C-G, MetaLR 0.17, MetaSVM -0.84
- S115S (p.Ser115Ser), rs548502111, gnomAD 10-102397005-G-A, CADD 8.04
- E116E (p.Glu116Glu), gnomAD 10-102397008-G-A, CADD 10.60
- G118W (p.Gly118Trp), gnomAD 10-102397012-G-T, MetaLR 0.43, MetaSVM 0.03
- G118R (p.Gly118Arg), gnomAD 10-102397012-G-A, MetaLR 0.40, MetaSVM -0.10
- G118G (p.Gly118Gly), gnomAD 10-102397014-G-A, CADD 12.00
- C120C (p.Cys120Cys), rs373367494, gnomAD 10-102397020-C-T, CADD 10.00
- A121T (p.Ala121Thr), rs781738940, ClinGen CA5664511, cosmic curated COSV10800, ClinVar RCV003583472, CADD 17.60, PolyPhen-2 0.00, Uncertain significance, Immunodeficiency, common variable, 10
Public NFKB2 analysis runs
- NFKB2 analysis run — NFKB2 (1,020 variants) — completed 2026-08-20